Paget's Disease News and Research

RSS

Paget’s disease of the bone is a chronic ailment affecting the skeleton. Sir James Paget described Paget's disease of bone in 1877 and the disease is named after him. This is a rare disease affecting 1% of the population in the United States. It commonly affects the elderly and nearly 3 to 4% of the population over age 50 are affected.

Teeth may be able to preserve antibodies for hundreds of years, study reveals

Teeth could be capable of preserving antibodies for hundreds of years, allowing scientists to investigate the history of infectious human diseases, a new study has found.

16 Aug 2023

Researchers are developing calculator that weighs risk and benefit of taking osteoporosis drugs

Osteoporosis is a major, worsening public health problem and bisphosphonates which help restore a healthier balance of bone production and resorption, have been a relatively inexpensive, successful treatment, particularly for those at highest risk for fractures.

16 Nov 2022

Medical societies publish guidelines on how to treat pre-invasive lesions of the vulva

Four international medical societies have collaborated on consensus statements for physicians, published in the Journal of Lower Genital Tract Disease, about how to treat pre-invasive lesions of the vulva.

21 Jun 2022

Calcified Tissue International announces top 10 most impactful papers of 2019

Calcified Tissue International and Musculoskeletal Research is among the leading peer-reviewed journals publishing original preclinical, translational, and clinical research as well as expert reviews in the bone and musculoskeletal field.

13 Jun 2021

Older men are underdiagnosed and undertreated for osteoporosis

A new study reveals that many older men who experience a fracture are still underdiagnosed with and undertreated for osteoporosis.

6 Nov 2020

Researchers discover key signaling pathway in the pathogenesis of Paget's disease

Researchers from the University of California, Irvine, in collaboration with their colleagues from Beijing, China, have gained new insights into the development of poorly understood malignant skin cancers collectively known as Paget's disease.

26 Jun 2020

Reviews provide overview of advances in the knowledge of focal and sclerotic bone diseases

Recently, extraordinary progress has been made in our understanding of the mechanisms and molecular pathways underlying focal and sclerotic bone diseases, rare disorders which have a strong genetic component.

13 May 2019

Research findings suggest potential strategies to combat IBMPFD and other degenerative diseases

UCLA researchers have discovered the molecular basis of, and identified potential treatment for, an incurable disease known as inclusion body myopathy, Paget disease with frontotemporal dementia, or IBMPFD.

21 Mar 2017

New article shows taxonomic classification of rare genetic bone disorders based on metabolic phenotypes

An International Osteoporosis Foundation Working Group on Skeletal Rare Diseases has published a new classification of rare genetic metabolic bone disorders (RGMBDs) according to their metabolic pathogenesis.

18 Jun 2015

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire plc today announced that Natpara (parathyroid hormone) for injection is now available in the United States. The U.S. Food and Drug Administration approved Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism on January 23, 2015.

1 Apr 2015

Endocrine Society issues Clinical Practice Guideline on rare bone condition

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of Paget's disease of the bone, a condition where one or more bones in the body become oversized and weak.

23 Nov 2014

Researchers discover link between NOX4 enzyme and osteoporosis

Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that a group of collaborators have discovered a link between the enzyme NOX4 and development of osteoporosis.

21 Oct 2013

VCP gene mutations cause neurological conditions including IBMPFD and ALS

New research, published in Neuron, gives insight into how single mutations in the VCP gene cause a range of neurological conditions including a form of dementia called Inclusion Body Myopathy, Paget's Disease of the Bone and Frontotemporal Dementia (IBMPFD), and the motor neuron disease Amyotrophic Lateral Sclerosis (ALS).

14 Mar 2013

Study identifies how new ALS gene mutations cause other diseases of the brain, muscle and bone

Researchers supported by The ALS Association have discovered how mutations in new amyotrophic lateral sclerosis (ALS) genes cause not only ALS but also other diseases of the brain, muscle and bone.

4 Mar 2013

Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.

23 Nov 2012

New mouse model could foster ALS, Paget's and dementia breakthroughs

Efforts to treat disorders like Lou Gehrig's disease, Paget's disease, inclusion body myopathy and dementia will receive a considerable boost from a new research model created by UC Irvine scientists.

3 Oct 2012

FDA reviews safety issues of bisphosphonates for osteoporosis

An advisory committee for U.S. Food and Drug Administration meets Friday to review the safety of a popular class of osteoporosis drugs called bisphosphonates amid worry that their long-term use could cause rare fractures of the thighbones and affect the jawbone. The committee will evaluate whether women should temporarily stop using the drugs or use them for only a few years.

6 Sep 2011

Eli Lilly, Synthes collaborate to develop osteoinductive products

Synthes, Inc. and Eli Lilly and Company today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.

10 Jun 2011

$Bone building drugs bisphosphonates lead to only a marginally higher risk of fractures: Study$

Bone building drugs bisphosphonates lead to only a marginally higher risk of fractures: Study

According to a new study, nearly 78% of all Swedish women aged 55 years and older who sustained a thigh bone or femur fracture in 2008 had taken bisphosphonates for their osteoporosis. However the authors of the study published in the May 5 issue of the New England Journal of Medicine (NEJM) write that the absolute risk for such breaks is small enough to justify prescribing the drugs.

5 May 2011

IOF, ANZBMS to hold osteoporosis and bone meeting in Asia-Pacific region

IOF and the ANZBMS, together with the Japanese Bone and Mineral Research Society, invite researchers and clinicians with an interest in osteoporosis and bone research to attend the year's most important bone meeting in the Asia-Pacific region.

29 Apr 2011